NOVEL Health Strategies Presenting Ten Peer-Reviewed Studies at ISPOR 2013 European Annual Meeting in Dublin, Ireland

Share Article

Novel Health Strategies team selected for ten peer-reviewed presentations at ISPOR EU 2013.

NOVEL Health Strategies team is presenting ten studies at the ISPOR EU 2013 meeting in Dublin, Ireland. These presentations highlight trends in health economic, outcomes research and global market and pricing.

November 4, 2013
PCN161: Systematic Review of Patient Reported Outcomes in Chronic Myeloid Leukemia
PCN162: Patient Reported Outcomes In Metastatic Castration-Resistant Prostate Cancer
PSY3: Meta-Analysis of Efficacy of Romiplostim for Treatment of Immune Idiopathic Thrombocytopenia
PCN204: Novel Market Access Models for Cancer Drugs

November 5, 2013
PHP194: Systematic Review on Use of Economic Evidence by Clinical Guidelines
PSS42: A Systematic Review of Patient Reported Outcomes in Glaucoma
PMS7: Meta-Analysis of Efficacy of Etanercept for Treatment of Psoriatic Arthritis
PCV17: Meta-Analysis of Safety of Dabigatran and Warfarin for Treatment of Atrial Fibrillation
PHP52: Importance of Subgroup Analyses for Health Technology Assessments

November 6, 2013
PUK11: In-Patient Hospitalizations for Chronic Kidney Disease in the United States

About Novel Health Strategies
Novel Health Strategies ("NOVEL") is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access. NOVEL has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. Novel Health has a large network of internal and external stakeholders and has published several thought leading strategy perspectives. NOVEL Health has presented industry trends and perspectives at ISPOR, AMCP and BIO meetings.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rob Aggarwal